Leukemia (2013) 27, 1754-1757; doi:10.1038/leu.2013. 12 The recurrent IGH translocations in myeloma define biologically important subgroups of disease that are not only associated with prognosis, but are also characterised by the unique overexpression of potentially targetable proteins. [1] [2] [3] [4] Inhibitors of MMSET or FGFR3, both overexpressed in t(4;14) myeloma, or MEK kinase inhibitors, targeting downstream effectors of MAF in cases with t(14;16), are currently under development. [5] [6] [7] Thus, identifying these translocation groups in the clinic will become essential for a personalised treatment approach. Expression of a translocation target gene together with the expression of a D group cyclin has been used as a disease classifier for myeloma (TC classification). 1, 8 Here, we have developed a novel test for the detection of the TC groups using multiplexed real-time quantitative reverse transcriptase-PCR (qRT-PCR). The assay assesses the expression of the translocation target genes FGFR3 and MMSET (overexpressed in t(4;14)), CCND1 (overexpressed in t(11;14)), MAF (overexpressed in t(14;16)), MAFB (overexpressed in t(14;20)), ITGB7 and CX3CR1 (overexpressed in t(14;16) and t(14;20)), CCND3 (overexpressed in t(6;14)), CCND2 (overexpressed secondary to MAF/MAFB), CKS1B (amplified in gain(1q)), relative to the housekeeping gene GAPDH in five parallel real-time PCR reactions. The test is designed to run on a standard real-time PCR cycler using standard reagents (Supplementary Methods).
The assay was validated in 255 presentation bone marrow myeloma samples from patients treated in the MRC Myeloma IX trial. 9 Sorting of myeloma cells, methods of RNA isolation and cDNA synthesis were performed following standard protocols. Interphase fluorescence in situ hybridisation (FISH) data were available for all patients. Details regarding the Myeloma IX trial, patient characteristics and sample processing can be found in Supplementary Methods. Target gene expression was assayed for all 255 samples using qRT-PCR and relative quantitative (RQ) values of expression were calculated (Supplementary Methods). RQ values were compared between translocation groups defined by FISH, namely t(4;14), t(11;14), t(14;16), t(14;20), t(6;14) and hyperdiploid samples. A small group of samples had no translocation or hyperdiploidy by FISH (termed 'Unknown') or a disrupted IGH@ locus with an unknown translocation partner (termed 'IGH split').
The different translocation groups were characterised by marked differences in specific gene expression patterns ( Figure 1 Figures 1b and c) . Twelve of the 45 cases (26.7%) with a t(4;14) did not express FGFR3, consistent with previous findings. 10 Overall survival (OS) for these patients did not differ from t(4;14) cases expressing FGFR3. In addition, expression of CCND2 was significantly higher in the t(4;14) group than in the non-t(4;14) group (mRQ: 11799 vs 7041, respectively; Po0.0001).
Overexpression of CCND1 was characteristic for the t(11;14) group compared with the non-t(11;14) group (mRQ: 69233 vs 2416; Po0.0001; Figure 1d ). Interestingly, expression of MMSET in the t(11;14) group was significantly higher than in the hyperdiploid group (mRQ: 756 vs 290; Po0.0001).
In the t(14;16) group (n ¼ 7), MAF was significantly overexpressed in comparison with the non-t(14;16) group (mRQ: 8000 vs 710; P ¼ 0.0003; Figure 1e ). MAFB expression was low or absent in patients with t(14;16). MAFB expression was high in the t(14;20) group and lower in the non-t(14;20) group (mRQ: 153,320 vs 2287; P ¼ 0.002; Figure 1f ). The genes ITGB7 and CX3CR1 were highly expressed in the group comprising t(14;16) and t(14;20) samples in comparison with samples without these translocations (mRQ ITGB7: 219,554 vs 7273; Po0.0001; mRQ CX3CR1: 8564 vs 194; P ¼ 0.0086, respectively; Figure 1g ).
As previously reported, the expression of cyclin D genes was generally mutually exclusive.
8 CCND2 expression was high in t(4;14), t(14;16) and t(14;20) samples (mRQ: 11799, 52944 and 44179, respectively) and low in t(11;14) cases (mRQ: 255), whereas CCND1 expression was very low or absent in t(4;14), t(14;16) and t(14;20) groups and high in the t(11;14) group. Very high expression of CCND3 in the two t(6;14) cases (RQ: 246,336 and 12,620,936 vs mRQ: 9086 in the non-t(6;14) group) was accompanied by low CCND1 and CCND2 expression. Hyperdiploid samples expressed cyclin D genes at lower levels than samples with a translocation (CCND1 mRQ: 1453; CCND2 mRQ: 2406; CCND3 mRQ: 6837), but most samples showed the same mutual exclusivity of cyclin D gene expression. However, a subset of patients in the hyperdiploid group did express CCND1 and CCND2, reminiscent of the D1 þ D2 TC group. 8 Elevated CKS1B mRNA expression had been associated with amplification of chromosome 1q in multiple myeloma. 11, 12 Expression of CKS1B was significantly higher in samples with gain of 1q than in those without (mRQ: 4534 vs 1921; P ¼ 0.0009), but groups overlapped widely. CKS1B expression alone was not powerful enough to predict the presence of an amplification of chromosome 1q with accuracy and was not associated with differences in survival in our data set.
On the basis of the characteristic differences in expression values between the FISH-defined translocation groups, a Supplementary Table S4 . Samples were sorted for presence of a translocation by FISH. Translocation groups as determined by gene expression (upper bar) and by FISH (lower bar) are colour-coded. Equivalents to the TC classification groups D1, D2 (expression of either CCND1 or CCND2) and D1 þ D2 (defined by RQ41000 of CCND1 and CCND2) within the hyperdiploid samples are indicated. (b-g) Expression differences in translocation target genes for the FISH-defined groups with t(4;14) (b, c), t(11;14) (d), t(14;16) (e), t(14;20) (f ) and the combination of the latter two (g). Gene expression is compared with samples lacking the specific translocation by FISH and excludes cases with t(4;14) for plots e to g. Box plots represent median expression with 25% and 75% percentiles. Whiskers represent 2.5% and 97.5% percentiles. Asterisks (*) mark statistically significant differences in gene expression between groups (Mann-Whitney-U, Pp0.0001). Please note that Y axes have been split for improved readability.
Accepted article preview online 16 January 2013; advance online publication, 5 February 2013 hierarchically structured algorithm was defined to predict the presence of the recurrent translocations based on qRT-PCR results in the same cohort of patients (Supplementary Figure  S1) . Using this approach, we were able to predict the translocation status of an individual sample for the recurrent translocations affecting the chromosomal regions on 4p16, 11q13, 16q23, 20q12 and 6p21 using fixed RQ value thresholds. The presence of t(4;14) and t(11;14) was predicted with a sensitivity of 96% and 100% and a specificity of 100% and 96%, respectively. Letters to the Editor 71% and 80% sensitivity, respectively, and 100% specificity for both lesions. The two samples with t(6;14) were correctly predicted based on their gene expression values (Supplementary Table S1 ).
We evaluated the potential causes for some of the false-positive cases, which had been assigned to a translocation group based on expression, but for which no recurrent translocation was detected by FISH. We were able to confirm a t(4;14) translocation in a sample that had been predicted 4p16 by our assay by detection of an IGH-MMSET fusion transcript by RT-PCR, as described in Keats et al., (data not shown). 10 A split IGH@ region had been detected by FISH in this case, but the translocation partner could not be determined. We know of another independent t(4;14) sample in which the translocation could not be detected using standard FISH probes, but was confirmed by breakpoint sequencing. In another case for which t(11;14) had been predicted based on expression, the translocation was confirmed by targeted nextgeneration sequencing of the IGH@ locus. In three other cases with a translocated 11q13 based on expression, rare genetic alterations involving the CCND1 locus on 11q13 were detected by FISH and karyotyping, including amplifications, complex rearrangements and deletions. These results indicate that, in some cases, our approach is able to identify translocations that are difficult or impossible to detect using standard diagnostic FISH probes.
We next analysed the impact of the expression-based translocation prediction on prognosis. Median OS for the three largest groups defined by translocations to 4p16 [n ¼ 45], 11q13 [n ¼ 55] and samples without overexpression of translocated genes [n ¼ 141] was 35.8 months, 51.6 months and 44.2 months, respectively (log-rank P ¼ 0.013; Figure 2a) . When comparing 4p16 with non-4p16 translocated cases, presence of the translocation was associated with a significantly shorter median OS (35.8 months vs 47.6 months; log-rank P ¼ 0.009). Median OS for the 16q23 [n ¼ 7] and the 20q12 [n ¼ 5] groups was 52.1 and 25.8 months, respectively. Of the three 6p21 translocated samples, one was alive after 85.5 months whereas the other two died after 31.2 and 61.7 months. These results are in line with our findings on the prognostic impact of cytogenetic lesions in the Myeloma IX cohort based on FISH data. 3 In addition, we were able to differentiate prognostic subgroups within the 4p16 samples based on CCND3 gene expression values. Median OS for the group expressing CCND3 equal or above an RQ value of 3000 (n ¼ 33) was 40.9 months compared with 16.6 months for the group expressing CCND3 below that threshold (n ¼ 12; Log-rank P ¼ 0.004; Figure 2b ). The association between CCND3 expression RQo3000 and survival retained its statistical significance in multivariate analysis including established high risk factors of known relevance within the t(4;14) group, like ISS, del(17p), gain 1q and patient age (P ¼ 0.05, HR 4.1 (95% CI 1.5-11)).
Prognostically relevant genetic features in myeloma that cannot be detected by our assay are gain(1q) and del(17p). It has recently been reported that gain(1q), but not del(17p), can be predicted using RNA microarray data. 13 Thus, testing for del(17p) has to be performed by FISH until potential novel methods such as nextgeneration sequencing become largely available. The same applies to gain(1q) in cases where RNA microarray data is not available.
In summary, we present here a qRT-PCR assay that allows for the rapid detection of the common and clinically relevant recurrent translocations in patients with multiple myeloma requiring minimal technical and financial resources. This novel assay might be useful for the diagnostics for multiple myeloma, particularly for screening of individual patients for risk-adapted or targeted treatment approaches. Its prognostic value can be further improved by combination with FISH assays for del(17p) and gain(1q). 
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